IMS MAXIMS Launches Software to Support Dementia Challenge

IMS MAXIMSIMS MAXIMS, a supplier of end-to-end electronic patient record systems, has launched software designed specifically to support NHS trusts with early diagnosis and improved care of patients with dementia. The MAXIMS Dementia System has been developed to meet the increasing demand from NHS organisations for a solution that not only prompts healthcare professionals to make relevant assessments for people with suspected dementia but one that also guides them to the correct care pathway to ensure that they receive the most appropriate referral and treatment.

Dementia affects an estimated 670,000 people in England alone, with this figure expected to double in the next 30 years. This is already resulting in more than 25% of general hospital beds at any one time being occupied by patients who have been diagnosed with dementia.

As part of the government's drive to ensure patients are diagnosed as early as possible and treated in the correct care setting, the Department of Health has introduced a Commissioning for Quality Innovation (CQUIN) payment framework, which incentivises the identification of patients with dementia as well as prompting appropriate referral and follow up. In addition to this, as of April 2013, the framework will be extended further to show how quality dementia care is being delivered.

Shane Tickell, CEO of IMS MAXIMS, said: "The misdiagnosis and delayed or incorrect treatment of long term conditions such a dementia is placing a huge strain on our NHS, with dementia estimated to cost our society in excess of £19 billion per year.

"IMS MAXIMS recognises the increasing need for trusts to manage the identification and referral process of dementia patients. Our aim is to help trusts capture data as easily and effectively as possible to improve the identification, and quality of care of dementia patients and receive the correct payments for doing so."

The IMS MAXIMS dementia software has been developed based on NICE guidelines and by working in partnership with NHS organisations aiming to improve their patient care pathways. The software, which integrates with virtually any system, takes users step-by-step through each of the CQUIN target's three stages (Find, Assess & Investigate, Review (FAIR)) allowing trusts to easily collate data ready for extraction. It can also be tailored so that clinical users establish a simple workflow, identifying dementia symptoms and other cognitive impairments early, resulting in more accurate referrals to the appropriate diagnostic assessment, treatment and support.

A dementia record is created for each patient who meets criteria set within the CQUIN framework; clinical users then follow a simple work-list within the software to complete the FAIR process:

  • Find - using the software's Confusion Assessment Screening, users can identify whether patients have delirium or dementia within 72 hours of admittance;
  • Assess & Investigate - conducting an Abbreviated Mental Test Score, investigate other potential diagnosis (clinical notes can be created and User Defined Assessments enabled to support FAIR process);
  • Referral - specialist diagnostic advice and follow up means healthcare professionals can direct patients, their carers and families to the correct services and support they need.

Currently only around 42% of people with dementia in England have a formal diagnosis. IMS MAXIMS software not only automatically directs clinical users through the FAIR process helping to reduce this figure, but also assists in identifying other causes and diagnosis of cognitive impairment, leading to reduced lengths of stay, improved efficiency of discharges, fewer readmissions and inter-ward transfers.

Tickell added: "IMS MAXIMS is committed to developing systems that support the increasing and ever changing challenges that the NHS faces. Working within the CQUIN framework has allowed us to develop software, which helps trusts become more efficient in administrative terms whilst improving patient well-being and care. We look forward to continuing to work alongside healthcare organisations to provide the most advanced IT solutions possible to address the issues they face."

About IMS MAXIMS
IMS MAXIMS is an electronic patient record provider working towards better, safer patient care. Specialists in developing clinical and administrative software solutions for healthcare providers, IMS MAXIMS currently supports more than 150 organisations, 11 million patient records in the UK, and 1.9 million patient records in Ireland, approx 50% of the population, as well as 20,000 users of IMS MAXIMS products.

MAXIMS is at the heart of the clinical and administrative life of everything from large UK and Irish hospitals, to small specialist independent clinics. It gives patient data to clinicians in exactly the format they need, and allows it to be shared with colleagues and updated in real-time. MAXIMS suits any clinical specialism and is excellent for order communications and reporting. Medical and administrative records can be kept fully up to date, with minimum effort. MAXIMS is web-based so there is no need to install software on computers or invest in expensive extra hardware.

Most Popular Now

European Artificial Intelligence Act Com…

The European Artificial Intelligence Act (AI Act), the world's first comprehensive regulation on artificial intelligence, enters into force. The AI Act is designed to ensure that AI developed and used...

Patient Safety must be Central to the De…

An EPR system brings together different patient information in one place, making it easier to access for healthcare professionals. This information can include patients' own notes, test results, observations by...

ChatGPT Shows Promise in Answering Patie…

The groundbreaking ChatGPT chatbot shows potential as a time-saving tool for responding to patient questions sent to the urologist's office, suggests a study in the September issue of Urology Practice®...

Survey: Most Americans Comfortable with …

Artificial intelligence (AI) is all around us - from smart home devices to entertainment and social media algorithms. But is AI okay in healthcare? A new national survey commissioned by...

AI Spots Cancer and Viral Infections at …

Researchers at the Centre for Genomic Regulation (CRG), the University of the Basque Country (UPV/EHU), Donostia International Physics Center (DIPC) and the Fundación Biofisica Bizkaia (FBB, located in Biofisika Institute)...

Video Gaming Improves Mental Well-Being

A pioneering study titled "Causal effect of video gaming on mental well-being in Japan 2020-2022," published in Nature Human Behaviour, has conducted the most comprehensive investigation to date on the...

New Diabetes Research Links Blood Glucos…

As part of its ongoing exploration of vocal biomarkers and the role they can play in enhancing health outcomes, Klick Labs published a new study in Scientific Reports - confirming...

Machine learning helps identify rheumato…

A machine-learning tool created by Weill Cornell Medicine and Hospital for Special Surgery (HSS) investigators can help distinguish subtypes of rheumatoid arthritis (RA), which may help scientists find ways to...

New AI Software could Make Diagnosing De…

Although Alzheimer's is the most common cause of dementia - a catchall term for cognitive deficits that impact daily living, like the loss of memory or language - it's not...

A New AI Tool for Cancer

Scientists at Harvard Medical School have designed a versatile, ChatGPT-like AI model capable of performing an array of diagnostic tasks across multiple forms of cancers. The new AI system, described Sept...

Vision-Based ChatGPT Shows Deficits Inte…

Researchers evaluating the performance of ChatGPT-4 Vision found that the model performed well on text-based radiology exam questions but struggled to answer image-related questions accurately. The study's results were published...

Bayer Launches New Healthy-Aging Ecosyst…

Combining a scientifically formulated dietary supplement, a leading-edge wellness companion app, and a saliva-based a biological age test by Chronomics, Bayer is taking a big step in the emerging healthy-aging...